Exelixis is transforming the challenges of drug development into opportunities to create innovative therapies with significant clinical and commercial potential.

Corporate Profile

Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer.

Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounMore >>

EXEL (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.09 (1.05%)
Data as of 07/22/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
07/22/16Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx™ (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy Printer Friendly Version
07/12/16Exelixis to Release Second Quarter 2016 Financial Results on Wednesday, August 3, 2016Printer Friendly Version
06/06/16Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX™ (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO Annual MeetingPrinter Friendly Version
06/05/16Exelixis and Its Partner Ipsen Announce Phase 3 Trial Results of CABOMETYX™ (Cabozantinib) Tablets Demonstrating Significant Overall Survival Benefit for Previously Treated Patients with Advanced Renal Cell Carcinoma Presented at ASCOPrinter Friendly Version
Upcoming EventsMore >>
Q2 2016 Exelixis Inc. Financial Results Conference Call
Wednesday, August 3, 2016 5:00 p.m. ET
Add to Calendar Add Q2 2016 Exelixis Inc. Financial Results Conference Call to Calendar  Help
remind me days before the event

Enter your e-mail address 
Featured Report
Download Documentation2015 Annual Report (pdf)
Download Documentation2014 Annual Report (pdf)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.